Study ANRS12417 - TOPCHIB
Interventional study of the efficacy of Tenofovir disoproxil fumarate (TDF) in preventing mother-to-child transmission of HBV in Tokombéré, Cameroon, in pregnant women infected with the hepatitis B virus (HBeAg positive or with a high viral load) whose newborns were vaccinated at birth.
Last updated on 15 July 2024
Presentation of the TOPCHIB study
The ANRS 12417 TOPCHIB study is designed to evaluate the feasibility, efficacy and cost-effectiveness of an antiviral treatment to be delivered to pregnant women with a high viral load or detectable hepatitis B virus e antigen (HBeAg) in a rural region where hepatitis B is highly endemic in Cameroon, in order to prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in a real-life setting. The study will be carried out in the Tokombéré district, where the prevalence of hepatitis B is around 20% and where antiviral treatment of pregnant women has long been successfully introduced to prevent MTCT of HIV.
Principal investigator
For Cameroon: : Jean-Pierre ADOUKARA/Dourwe MAAGA
For France : Françoise LUNEL-FABIANI
Pathology
Hepatitis B
Planning
Start date: 22 August 2023
End of study: second half of 2026
Status
In progress
Sponsor
Inserm-ANRS MIE
You are participating or have participated in this study
On the form above, you will find information on the ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.
If you would like to find out more about your participation in a clinical study, please see the section below.
Visit the participant area